Langrish C - Search Results

1

Erector spinae plane block facilitating rapid weaning in an anticoagulated V-V ECMO patient with chest trauma.

Silhi RP, Langrish C, Camporota L. Silhi RP, et al. Among authors: langrish c. Perfusion. 2025 Sep 6:2676591251377577. doi: 10.1177/02676591251377577. Online ahead of print. Perfusion. 2025. PMID: 40913430

2

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design.

Ucpinar S, Kwan JK, Hoffman JD, Tilley MK, Douglas JA, Rubio RG, Lu R, Nunn PA, Langrish CL. Ucpinar S, et al. Among authors: langrish cl. Clin Transl Sci. 2024 Dec;17(12):e70094. doi: 10.1111/cts.70094. Clin Transl Sci. 2024. PMID: 39604226 Free PMC article. Clinical Trial.

3

Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.

Smith CW, Campos J, Brown HC, Jooss NJ, Ivanova VS, Harbi M, Garcia-Quintanilla L, Jossi S, Perez-Toledo M, Rookes K, Brill A, Theodore LN, Owens T, LaStant J, Foulke MC, Mukai S, Francesco M, Storek M, Hicks A, Langrish C, Nunn PA, Cunningham AF, Chauhan A, Thomas MR, Watson SP, Nicolson PLR. Smith CW, et al. Among authors: langrish c. Blood Adv. 2024 Nov 12;8(21):5557-5570. doi: 10.1182/bloodadvances.2024012713. Blood Adv. 2024. PMID: 38968150 Free PMC article.

4

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Owens TD, Brameld KA, Verner EJ, Ton T, Li X, Zhu J, Masjedizadeh MR, Bradshaw JM, Hill RJ, Tam D, Bisconte A, Kim EO, Francesco M, Xing Y, Shu J, Karr D, LaStant J, Finkle D, Loewenstein N, Haberstock-Debic H, Taylor MJ, Nunn P, Langrish CL, Goldstein DM. Owens TD, et al. Among authors: langrish cl. J Med Chem. 2022 Apr 14;65(7):5300-5316. doi: 10.1021/acs.jmedchem.1c01170. Epub 2022 Mar 18. J Med Chem. 2022. PMID: 35302767

5

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).

Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, Hartmann S, Francesco MR, Langrish CL, Nunn PA, Gourlay SG. Owens TD, et al. Among authors: langrish cl. Clin Transl Sci. 2022 Feb;15(2):442-450. doi: 10.1111/cts.13162. Epub 2021 Nov 12. Clin Transl Sci. 2022. PMID: 34724345 Free PMC article. Clinical Trial.

6

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.

Xing Y, Chu KA, Wadhwa J, Chen W, Zhu J, Bradshaw JM, Shu J, Foulke MC, Loewenstein N, Nunn P, By K, Phiasivongsa P, Goldstein DM, Langrish CL. Xing Y, et al. Among authors: langrish cl. Immunohorizons. 2021 Jul 29;5(7):581-589. doi: 10.4049/immunohorizons.2100063. Immunohorizons. 2021. PMID: 34326199 Free article.

7

A survey on the practices and capabilities in the management of respiratory failure in South East England.

Jha A, Vasques F, Sanderson B, Daly K, Glover G, Ioannou N, Wyncoll D, Sherren P, Langrish C, Meadows C, Retter A, Paul R, Barrett NA, Camporota L. Jha A, et al. Among authors: langrish c. J Intensive Care Soc. 2021 May;22(2):175-181. doi: 10.1177/1751143720928895. Epub 2020 Jun 1. J Intensive Care Soc. 2021. PMID: 34025757 Free PMC article.

8

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, LaStant J, Bisconte A, Outerbridge C, White SD, Hill RJ, Brameld KA, Goldstein DM, Nunn PA. Langrish CL, et al. J Immunol. 2021 Apr 1;206(7):1454-1468. doi: 10.4049/jimmunol.2001130. Epub 2021 Mar 5. J Immunol. 2021. PMID: 33674445 Free PMC article.

9

Safety of Percutaneous Dilatational Tracheostomy During Veno-Venous Extracorporeal Membrane Oxygenation Support in Adults With Severe Respiratory Failure.

Dimopoulos S, Joyce H, Camporota L, Glover G, Ioannou N, Langrish CJ, Retter A, Meadows CIS, Barrett NA, Tricklebank S. Dimopoulos S, et al. Among authors: langrish cj. Crit Care Med. 2019 Feb;47(2):e81-e88. doi: 10.1097/CCM.0000000000003515. Crit Care Med. 2019. PMID: 30431492

10

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. Basler M, et al. Among authors: langrish cl. EMBO Rep. 2018 Dec;19(12):e46512. doi: 10.15252/embr.201846512. Epub 2018 Oct 2. EMBO Rep. 2018. PMID: 30279279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters